Skip to main content

Xilio Therapeutics, Inc.

corporate_fare Company Profile

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed XLO - Latest Insights

XLO
Apr 28, 2026, 5:02 PM EDT
Filing Type: DEF 14A
Importance Score:
9
XLO
Mar 23, 2026, 7:40 AM EDT
Filing Type: 10-K
Importance Score:
8
XLO
Mar 23, 2026, 7:38 AM EDT
Source: Reuters
Importance Score:
8
XLO
Mar 23, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
9
XLO
Mar 12, 2026, 8:34 AM EDT
Filing Type: 8-K
Importance Score:
8
XLO
Mar 12, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
XLO
Mar 09, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
XLO
Feb 24, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
XLO
Feb 17, 2026, 5:31 PM EST
Filing Type: 4
Importance Score:
8
XLO
Feb 12, 2026, 4:49 PM EST
Filing Type: 424B5
Importance Score:
9
XLO
Feb 11, 2026, 5:16 PM EST
Filing Type: 424B5
Importance Score:
7
XLO
Jan 26, 2026, 7:30 AM EST
Filing Type: DEF 14A
Importance Score:
8
XLO
Jan 16, 2026, 4:05 PM EST
Filing Type: PRE 14A
Importance Score:
8
XLO
Jan 08, 2026, 8:42 AM EST
Filing Type: 8-K
Importance Score:
9
XLO
Jan 05, 2026, 8:31 AM EST
Filing Type: 8-K
Importance Score:
9